BioSpace News Archive

CardioFocus, Inc. announced several milestones toward the development of a next generation pulse field ablation technology for treatment of AFib, including the formation of a clinical advisory board, filing of key patents and completing initial pre-clinical studies.

CD Genomics is a world-leading genomics services company that continues to innovate in sequencing services for the genomics industry as well as genotyping, library construction, bioinformatics, microarrays, mutagenesis analysis, and more.

NovAccess Global Inc. announced the filing of an application with the U.S. Food and Drug Administration to receive Orphan Drug Designation for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma multiforme and other high grade gliomas.

PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022.

LB Pharmaceuticals Inc (LB), a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today that details from its first Phase 1 clinical trial of LB-102 (NCT04187560) have been published.

Nortech Systems Incorporated (Nasdaq: NSYS), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical, aerospace & defense and industrial markets, will hold a live conference call and webcast at 4:00 p.m. central time on Wednesday, August 10, 2022, to discuss the company’s second quarter financial results.

Replica Analytics, an Aetion company, has unveiled a novel approach to use synthetic data for a more accurate assessment of re-identification risks in datasets, to better manage privacy risks and enable greater data sharing in healthcare and other sectors.

Ascentage Pharma and Innovent Biologics, Inc. announce that the Center for Drug Evaluation of China National Medical Products Administration has accepted and granted Priority Review designation to a New Drug Application that will support the full approval of olverembatinib in patients with chronic-phase chronic myeloid leukemia who are resistant and/or intolerant of first- and second-generation tyrosine kinase inhibitors.

A while ago, some researchers had suggested that blocking a set of proteins, known as bromodomain and extraterminal proteins, might be a way to fight COVID-19.

According to Report Study, the global 3D printing in medical application market size is expected to surpass around USD 5.89 billion by 2030, poised to grow at a CAGR of 23.28% from 2022 to 2030.